このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

再発性または難治性の急性リンパ芽球性白血病の参加者の治療におけるペムブロリズマブとブリナツモマブ

2026年10月26日 更新者:City of Hope Medical Center

再発/難治性急性リンパ芽球性白血病患者におけるペンブロリズマブとブリナツモマブの併用の第1/2相試験

This phase I/II studies the side effects of pembrolizumab and blinatumomab and to see how well they work in treating participants with acute lymphoblastic leukemia that has come back or has not responded to the treatment. Monoclonal antibodies, such as pembrolizumab and blinatumomab, may interfere with the ability of tumor cells to grow and spread.

調査の概要

詳細な説明

PRIMARY OBJECTIVES:

I. Assess the safety and tolerability of combination immunotherapy with blinatumomab and pembrolizumab by evaluation of toxicities including: type, frequency, severity, attribution, time course and duration. (Phase 1) II. Determine the recommended phase 2 schedule of combination immunotherapy with pembrolizumab and blinatumomab. (Phase 1) III. Evaluate the anti-leukemia activity of combination immunotherapy blinatumomab and pembrolizumab as assessed by overall response rate (complete response [CR] or CR with incomplete recovery [CRi]). (Phase 2)

SECONDARY OBJECTIVES:

I. Estimate time to response (CR or CRi) and response duration. (Phase 2) II. Estimate overall survival and event-free survival. (Phase 2) III. Determine the number and proportion of patients who underwent hematopoietic stem cell transplantation (HSCT) after treatment of pembrolizumab and blinatumomab. (Phase 2) IV. Determine the number and proportion of patients who receive pembrolizumab maintenance and the proportion continuing for up to 1 year. (Phase 2) V. Estimate the minimal residual disease rate. (Phase 2)

CORRELATIVE OBJECTIVES:

I. Explore evolution of T cell subsets at various points in treatment (T naive, T effector, T effector memory, T central memory, CD4, CD8). (Phase 2) II. Evaluate PD-L1 expression levels on acute lymphoblastic leukemia (ALL) blasts and blasts counts overtime. (Phase 2) III. Evaluate PD-1/PD-L1 expression on subsets of T cells. (Phase 2) IV. Evaluate the clonal evolution of leukemic blasts in response to treatment. (Phase 2)

OUTLINE:

Participants receive pembrolizumab intravenously (IV) over 30 minutes on day 15 of cycle 1 and days 1 and 22 of cycles 2 -5, and blinatumomab IV on days 1-28. Treatment repeats every 35-42 days for up to 5 cycles in the absence of disease progression or unacceptable toxicity. Patients who achieve complete response have the option to receive blinatumomab IV for up to 4 additional cycles.

After completion of study treatment, participants are followed up at 30 days and then every 3 months for 1 year.

研究の種類

介入

入学 (実際)

26

段階

  • フェーズ2
  • フェーズ 1

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

    • California
      • Duarte、California、アメリカ、91010
        • City of Hope Medical Center

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年歳以上 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  • Previously treated ALL including philadelphia chromosome (BCR-Ab1) positive ALL who meet all of the following criteria:

    • Diagnosis of CD19-positive B-cell ALL based on the flow cytometry and histology
    • Previously treated subjects with primary refractory disease OR after first or subsequent relapse
    • Subjects with detectable lymphoblasts in bone marrow (BM) or extramedullary disease (EMD) that is radiographically measurable and amenable to repeat biopsies
  • Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1

  • Left ventricular ejection fraction (LVEF) > 45%

  • Pulmonary function tests diffusing capacity of the lungs for carbon monoxide (DLCO) (adjusted for hemoglobin) > 50% predicted

  • Serum creatinine =< 1.5 X upper limit of normal (ULN) OR measured or calculated creatinine clearance (glomerular filtration rate [GFR] can also be used in place of creatinine or creatinine clearance [CrCl]) >= 60 ml/min for subject with creatinine levels > 1.5 X institutional ULN

  • Serum total bilirubin =< 1.5 X ULN OR direct bilirubin =< ULN for subjects with total bilirubin levels > 1.5 ULN

  • Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) and alanine transaminase (serum glutamic pyruvic transaminase [SGPT]) =< 2.5 X ULN OR =< 5 X ULN for subjects with liver metastases

  • Albumin >= 2.5 mg/dL

  • International normalized ratio (INR) or prothrombin time (PT) =< 1.5 X ULN unless subject is receiving anticoagulant therapy as long as PT or partial thromboplastin time (PTT) is within therapeutic range of intended use of anticoagulants

  • Activated partial thromboplastin time (aPTT) =< 1.5 X ULN unless subject is receiving anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use of anticoagulants

  • Beta human chorionic gonadotropin (beta HCG) negative

  • Human immunodeficiency virus (HIV): negative HIV antibody / polymerase chain reaction (PCR)

  • Hepatitis B virus (HBV): negative hepatitis B surface antigen (HBsAg) and negative hepatitis B core (HBc) antibody or positive HBc and negative HBV deoxyribonucleic acid (DNA) by quantitative PCR

  • Hepatitis C virus (HCV): negative viral ribonucleic acid (RNA) (if HCV antibody is positive)

  • Required screening laboratory data (within 28 days prior to administration of pembrolizumab)

  • Discontinuation of all therapy (including radiotherapy, chemotherapy, tyrosine-kinase inhibitors [TKIs], immunotherapy or investigational therapy) for the treatment of cancer as follows:

    • At least 1 week or 5 half-lives (whichever is longer) from the last dose of prior anti-cancer therapy and the initiation of study therapy

    • Exceptions or modifications to the above are as follows:

      • Medications that are typically part of a maintenance therapy for ALL, such as glucocorticoids or mercaptopurine, may be administered up to 3 days prior to the first dose, except vinca alkaloids which must be discontinued at least 14 days prior to the start of study treatment; TKIs are not permitted to be continued at screening (e.g. Gleevec)
    • Intrathecal (IT) chemotherapy may be dosed up to 7 days prior to first dose of pembrolizumab (cytarabine [Ara-C] recommended)

    • For biologics (e.g. monoclonal antibodies), washout period of 1 month beyond the recommended dosing interval and at least 4 weeks or 5 half-lives (whichever is longer) since the last dose

  • All acute toxic effects of any prior antitumor therapy must be resolved to grade =< 1 before enrollment, with the exception of alopecia (any grade permitted), or bone marrow parameters (any grades permitted)

  • For female subjects of childbearing potential, willingness to abstain from heterosexual intercourse or use 2 concurrent protocol recommended methods of contraception from the screening visit throughout the study treatment period and to 30 days from the last dose of pembrolizumab; a negative serum pregnancy test is required for female subjects at screening; lactating females must agree to discontinue nursing before administration of study drugs

  • For male subjects having intercourse with females of childbearing potential, willingness to abstain from heterosexual intercourse or use 2 protocol-recommended methods of contraception from the start of pembrolizumab throughout the study treatment period and for 90 days following the last dose of pembrolizumab; also, male subjects should refrain from sperm donation from the start of pembrolizumab throughout the study treatment period and for 3 months following the last dose of study drugs

  • In the judgment of the investigator, participation in the protocol offers an acceptable benefit-to-risk ratio when considering current disease status, medical condition, and the potential benefits and risks of alternative treatments for the subject's ALL

  • Willingness to comply with scheduled visits, drug administration plan, imaging studies, laboratory tests, other study procedures, and study restrictions; psychological, social, familial or geographical factors that might preclude adequate study participation should be considered

  • Have the ability to understand and sign a written informed consent form, which must be obtained prior to initiation of study procedures

Exclusion Criteria:

  • Diagnosis of mature B-cell ALL (Burkitt's leukemia) according to World Health Organization (WHO) classification, or lymphoid blast crisis of chronic myelogenous leukemia (CML)

  • A life threatening illness, medical condition or organ system dysfunction which, in the investigators' opinion, could compromise the subject's safety or interfere with the absorption or metabolism of pembrolizumab

  • Active or symptomatic central nervous system (CNS) disease

    • For study purposes, a subject will not be considered as having active CNS disease if the subject has documentation of prior CNS disease and has received prior treatment (IT or radiation) and is:

      • Asymptomatic for the last 28 days prior to screening and
      • Has documented at least 2 negative cerebrospinal fluid (CSF) cytology (which must include 1 lumbar puncture [LP] within the study screening window)
  • Uncontrolled undercurrent illness including but not limited to unstable angina pectoris or psychiatric illness/social situations that would limit compliance with study requirements; subjects with active infection are permitted to enroll provided that the infection is documented to be under control

  • History of myelodysplastic syndrome or organ transplantation

  • History of non-lymphoid malignancy except for the following:

    • Adequately treated local basal cell or squamous cell carcinoma of the skin, cervical carcinoma in situ, superficial bladder cancer, asymptomatic prostate cancer without known metastatic disease and with no requirement for therapy or requirement only hormonal therapy and with normal prostate specific antigen for > 1 year prior to the start of pembrolizumab, or any other cancer that has been in complete remission without treatment for >= 5 years prior to enrollment
  • Known hypersensitivity or intolerance to any of the active substance or excipients in the formulations for pembrolizumab and blinatumomab

  • Ongoing drug-induced liver injury, chronic active hepatitis C (HCV), chronic active hepatitis B (HBV), HIV, alcoholic liver disease, non-alcoholic steatohepatitis, cirrhosis of the liver, or portal hypertension

  • Prior allogeneic bone marrow transplantation

  • Pregnancy or breastfeeding

  • Has known history of, or any evidence of active, non-infectious pneumonitis

  • Concurrent participation in an investigational drug trial with therapeutic intent defined as prior study therapy within 28 days prior to start of this study

  • Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent

    • Note: subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study
    • Note: if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
  • Has active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs); replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment

  • Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial

  • Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the pre-screening or screening visit through 120 days after the last dose of trial treatment

  • Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or blinatumomab

  • Has received a live vaccine within 30 days of planned start of study therapy

  • Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:なし
  • 介入モデル:単一グループの割り当て
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:Treatment (pembrolizumab, blinatumomab)

Participants receive pembrolizumab intravenously (IV) over 30 minutes on day 15 of cycle 1 and days 1 and 22 of cycles 2 -5, and blinatumomab IV on days 1-28. Treatment repeats every 35-42 days for up to 5 cycles in the absence of disease progression or unacceptable toxicity. Patients who achieve complete response have the option to receive blinatumomab IV for up to 4 additional cycles.

Correlative studies

Given IV

他の名前:
  • ブリンサイト
  • 抗CD19×抗CD3バイスペシフィックモノクローナル抗体
  • 抗CD19/抗CD3組換えバイスペシフィックモノクローナル抗体 MT103
  • MEDI-538
  • MT-103

Given IV

他の名前:
  • キイトルーダ
  • MK-3475
  • ランブロリズマブ
  • SCH 900475

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Incidence of Dose-Limiting Toxicity (Phase 1)
時間枠:From the start of initial treatment up to 35 days

Number of participants experiencing at least one dose-limiting toxicity (DLT) during the DLT assessment period. Toxicities were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.

From the start of initial treatment up to 35 days
Response Rate (Phase 2)
時間枠:From the start of initial treatment till the end of protocol treatment, up to 5 cycles

Response was defined as complete response (CR)/CR with incomplete hematologic recovery (CRi) based on the National Comprehensive Cancer Network guidelines on acute lymphoblastic leukemia version 1 2017 response criteria.

From the start of initial treatment till the end of protocol treatment, up to 5 cycles

二次結果の測定

結果測定
メジャーの説明
時間枠
Incidence of Grade 3-5 Adverse Events
時間枠:From the start of initial treatment until protocol completion, up to 24 months after the end of treatment.

Toxicities were graded according to the National Cancer Institute-Common Terminology Criteria for Adverse Events version 5.0. Number of participants experiencing at least one Grade 3, 4, or 5 adverse event.

From the start of initial treatment until protocol completion, up to 24 months after the end of treatment.
Duration of Remission
時間枠:From the date of first documented CR/CRi until disease progression or the end of protocol follow-up, whichever occurs first.

Duration of remission is defined as the time from first documented complete response (CR) or complete response with incomplete hematologic recovery (CRi) to the earliest of disease progression or the end of protocol follow-up.

From the date of first documented CR/CRi until disease progression or the end of protocol follow-up, whichever occurs first.
Time to Response
時間枠:From date of first dose of study drug up to the end of study treatment

Time to response is defined as the time from the first dose of study treatment to the first documented objective response (complete response [CR] or complete response with incomplete hematologic recovery [CRi]).

From date of first dose of study drug up to the end of study treatment
Median Overall Survival
時間枠:From date of first dose of study drug up to 1 year

Overall survival is defined as the time from first dose of study treatment to death from any cause. Median overall survival was estimated using the Kaplan-Meier method

From date of first dose of study drug up to 1 year
Incidence of Relapse
時間枠:From date of first dose of study drug up to 1 year

Incidence of relapse is defined as the number of participants who experienced disease relapse after achieving a documented response (complete response [CR] or complete response with incomplete hematologic recovery [CRi]) during the protocol-defined follow-up period.

From date of first dose of study drug up to 1 year
Allogeneic Stem Cell Transplantation (SCT) Realization Rate
時間枠:From the end of study treatment through 1 year.

Allogeneic stem cell transplantation (SCT) realization rate was measured by number and proportion of patients who underwent SCT after treatment of pembrolizumab and blinatumomab.

From the end of study treatment through 1 year.
Number and Proportion of Patients Who Start Pembrolizumab Maintenance
時間枠:Up to 1 year
Up to 1 year
Number and Proportion of Patients Who Complete Pembrolizumab Maintenance
時間枠:Up to 1 year
Up to 1 year
Minimal Residual Disease Rate
時間枠:From the end of study treatment through 1 year.

Minimal residual disease (MRD) was measured by number and proportion of patients with CR/CRi who had confirmed minimal residual disease.

From the end of study treatment through 1 year.

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

捜査官

  • 主任研究者:Lihua Budde、City of Hope Medical Center

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2019年8月2日

一次修了 (実際)

2025年1月31日

研究の完了 (推定)

2027年9月29日

試験登録日

最初に提出

2018年4月5日

QC基準を満たした最初の提出物

2018年4月19日

最初の投稿 (実際)

2018年4月30日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月17日

QC基準を満たした最後の更新が送信されました

2026年10月26日

最終確認日

2026年10月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • 19017
  • 19017 (その他の識別子:City of Hope Medical Center)
  • NCI-2018-00526 (レジストリ識別子:CTRP (Clinical Trial Reporting Program))

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

はい

米国FDA規制機器製品の研究

いいえ

米国で製造され、米国から輸出された製品。

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する